Active, Not Recruiting
The Efficacy and Safety of Adjuvant Immunotherapy After Pathological Complete Response Following Neoadjuvant Chemoimmunotherapy in Patients with Resectable NSCLC
NCT06243679
- Conditions
- Resectable/Potentially Resectable NSCLC
- Locations
-
- Xiangya Hospital, Central South University Affiliated Changsha, Hunan, China